Literature DB >> 3192275

Immunopotentiation of the humoral response by liposomes: encapsulation versus covalent linkage.

E Shahum1, H M Thérien.   

Abstract

Two different modes of antigen association with liposomes were compared for their stimulation of IgM- and IgG-producing cells in primary- and secondary-response experiments. The study was carried out on BALB/c mice using the antigen bovine serum albumin either free, encapsulated in liposomes or covalently linked to the liposomal surface. Our results indicate that, although both types of liposome association are equally efficient in potentiating the humoral response, encapsulation mainly favours IgG isotype production with little or no effect on the IgM subset, while covalent linkage stimulates the production of both IgG and IgM. Our results reconcile some apparently conflicting published data and suggest that the mode of antigen association with liposomes considerably influences the pathways by which stimulation occurs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3192275      PMCID: PMC1384931     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  18 in total

Review 1.  Liposomes in therapeutic and preventive medicine: the development of the drug-carrier concept.

Authors:  G Gregoriadis
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

2.  Liposomes as immunological adjuvants.

Authors:  A G Allison; G Gregoriadis
Journal:  Nature       Date:  1974-11-15       Impact factor: 49.962

3.  Use of chromium chloride as the coupling agent in a modified plaque assay. Cells producing anti-protein antibody.

Authors:  G H Sweet; F L Welborn
Journal:  J Immunol       Date:  1971-05       Impact factor: 5.422

4.  Immune response mediated by liposome-associated protein antigens. II. Comparison of the effectiveness of vesicle-entrapped and surface-associated antigen in immunopotentiation.

Authors:  P N Shek; B H Sabiston
Journal:  Immunology       Date:  1982-12       Impact factor: 7.397

5.  Association of an albumin antigen with phosphatidylcholine liposomes alters the nature of immunoglobulins produced during the immune response against the antigen.

Authors:  N Van Rooijen; R Van Nieuwmegen
Journal:  Biochim Biophys Acta       Date:  1983-02-22

6.  Liposomes as immunological adjuvants in eliciting antibodies specific to the synthetic polypeptide poly(LTyr, LGlu)-poly(DLAla)--(LLys) with high frequency of site-associated idiotypic determinants.

Authors:  R Lifshitz; C Gitler; E Mozes
Journal:  Eur J Immunol       Date:  1981-05       Impact factor: 5.532

7.  Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside.

Authors:  L T Mimms; G Zampighi; Y Nozaki; C Tanford; J A Reynolds
Journal:  Biochemistry       Date:  1981-02-17       Impact factor: 3.162

8.  Immune response mediated by liposome-associated protein antigens. I. Potentiation of the plaque-forming cell response.

Authors:  P N Shek; B H Sabiston
Journal:  Immunology       Date:  1982-02       Impact factor: 7.397

9.  A new approach for the immunogenic presentation of membrane-bound human colon tumor antigens.

Authors:  B H Tom; T J Goodwin; J Sengupta; B D Kahan; L P Rutzky
Journal:  Immunol Commun       Date:  1982

10.  Major histocompatibility complex-restricted and unrestricted activation of helper T cell lines by liposome-bound antigens.

Authors:  P Walden; Z A Nagy; J Klein
Journal:  J Mol Cell Immunol       Date:  1986
View more
  8 in total

Review 1.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

2.  Lipid nanocapsule as vaccine carriers for his-tagged proteins: evaluation of antigen-specific immune responses to HIV I His-Gag p41 and systemic inflammatory responses.

Authors:  Saurabh Wadhwa; Anekant Jain; Jerold G Woodward; Russell J Mumper
Journal:  Eur J Pharm Biopharm       Date:  2011-10-31       Impact factor: 5.571

Review 3.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

Review 4.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

5.  Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Authors:  Mark T Orr; Christopher B Fox; Susan L Baldwin; Sandra J Sivananthan; Elyse Lucas; Susan Lin; Tony Phan; James J Moon; Thomas S Vedvick; Steven G Reed; Rhea N Coler
Journal:  J Control Release       Date:  2013-08-09       Impact factor: 9.776

Review 6.  Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.

Authors:  Luis O De Serrano; David J Burkhart
Journal:  J Nanobiotechnology       Date:  2017-11-17       Impact factor: 10.435

Review 7.  Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development.

Authors:  Jie Liang; Xiao Zhao
Journal:  Cancer Biol Med       Date:  2021-05-12       Impact factor: 4.248

8.  Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes.

Authors:  Christopher B Fox; Sean K Mulligan; Joyce Sung; Quinton M Dowling; H W Millie Fung; Thomas S Vedvick; Rhea N Coler
Journal:  Int J Nanomedicine       Date:  2014-03-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.